A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke
about
The use of flow cytometry to assess a novel drug efficacy in multiple sclerosisHLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.Sex-dependent treatment of chronic EAE with partial MHC class II constructs.Novel humanized recombinant T cell receptor ligands protect the female brain after experimental strokeDifferent immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune ExpansionSex differences in the immune response to experimental stroke: Implications for translational research.DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury.Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Partial MHC class II constructs as novel immunomodulatory therapy for stroke.Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear CellsDRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.
P2860
Q26824619-6BBDF017-E97E-418D-B204-30D5F57141C9Q33641609-8DDB916C-18E8-4706-A1F9-7DD980D3D03EQ33645392-2FF1B7B9-B8C9-4842-8200-68A27C7E9732Q34001070-61D6D0FE-6358-40DB-A39D-FA4CC12ECAC5Q34242088-A8A69BD8-1D62-4CF9-B3FF-83D8EF0AD5C8Q34476372-43A5370B-EA54-426F-8202-34ED13B387BFQ35782781-9F849B97-A64C-436B-A5E8-5FC74860A0D1Q36790648-ACD09990-20FD-4BBF-A891-81456E7E62B9Q37432327-5ADB6081-9A37-4753-B497-9473646C7B8AQ38743804-3E624709-EC33-423B-9F32-F9BFDC31FE81Q38791052-6195BBEB-C118-4BB6-A9E3-3E1A7291413DQ38988985-9969AEB1-A4C0-4A40-B7E6-A7D31E54FE6CQ40400293-D6D4B448-6C46-4AA9-840B-2E596454BFDDQ48011437-6F866D6C-EA10-4ABD-8793-A901324BD4B0
P2860
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke
@en
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.
@nl
type
label
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke
@en
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.
@nl
prefLabel
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke
@en
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke.
@nl
P2093
P2860
P1476
A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke
@en
P2093
Amanda Casper
Arthur A Vandenbark
Gil Benedek
Halina Offner
Nabil J Alkayed
Nicole Libal
Roberto Meza-Romero
Wenbin Zhu
Xiaolin Yu
P2860
P2888
P356
10.1007/S11011-013-9440-0
P577
2014-03-01T00:00:00Z